Saturday, May 14, 2022

PRESS RELEASE: First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

Aptorum Group Limited, a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office (“US PTO”) has granted the patent regarding the Rapid Pathogen Infectious Disease Liquid Biopsy Diagnostics (“RPIDD”) regarding the invention of an unbiased and simultaneous amplification method for DNA library preparation (US Patent No : US11,280,028 B1) to A*STAR institution, a Singapore based institution with whom Aptorum has an exclusive licensing agreement of the said technology. The RPIDD technology has been exclusively licensed by Aptorum from A*Star through its subsidiary, Aptorum Innovations Holding Pte Limited.

The RPIDD invention employs a unique method in preparing DNA libraries from samples which contain more than one type of nucleic acids in substantially low amount comparative to non-nucleic acid molecules in the sample within a remarkably shorter turnaround time and substantially more simplified steps compared to conventional methods of preparing DNA library.

Mr. Darren Lui, President and Executive Director of Aptorum Group Limited comments “Through our collaboration partner A*STAR, we are extremely delighted that the USPTO has recognised the uniqueness of our RPIDD technology and hence granted the said patent. The patented RPIDD method is going to revolutionize the traditional first line clinical diagnostics for infectious diseases such as blood culture, PCR (etc), and we are convinced that a rapid molecular liquid biopsy based diagnostics approach for infectious diseases will disrupt the current approaches and hence in due course potentially reduce infected patient’s mortality and morbidity. We are now spearheading the efforts in the ongoing clinical validation and pre-commercialisation preparation of our patented RPIDD.”

About Aptorum’s Rapid Pathogen Identification and Detection Diagnostics Technology (RPIDD)

RPIDD is an innovative liquid biopsy-driven rapid pathogen molecular diagnostics technology. Proprietary technologies are being developed to enrich pathogenic DNA / RNA for analysis through harnessing the power of Next-Generation Sequencing platforms and proprietary artificial intelligence-based software analytics with the goal to rapidly identify and detect any foreign pathogens (virus, bacteria, fungus, parasites) without bias through its genome composition and to identify other unknown pathogens and novel mutated pathogens. RPIDD has been and continues to be validated in human samples and so far, such testing has been able to detect pathogens – ranging from bacteria, fungi and viruses in an unbiased manner. RPIDD is currently under validation in-human.

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.

Engineers Develop Fast and Accurate Covid Sensor

Engineers at Johns Hopkins University, supported in part by the U.S. National Science Foundation, have developed a COVID-19 sensor that addresses the limitations of the two most widely used types of COVID-19 tests: PCR tests that require sample preparation, and the less accurate rapid antigen tests.

The sensor technology, which is not yet available, is almost as sensitive as a PCR test and as convenient as a rapid antigen test. The simple-to-use sensor doesn’t require sample preparation and can be used as disposable chips or on a wide variety of surfaces.

“The technique is as simple as putting a drop of saliva on our device and getting a negative or a positive result,” said Ishan Barman, one of the senior authors of the study. “The key novelty is that this is a label-free technique, which means that no additional chemical modifications like molecular labeling or antibody functionalization are required. The sensor could eventually be used in wearable devices.”

“Label-free optical detection, combined with machine learning, allows us to have a single platform that can test for a wide range of viruses with enhanced sensitivity and selectivity, with a very fast turnaround,” added lead author Debadrita Paria.

“Using state-of-the-art nanoimprint fabrication and transfer printing, we have realized highly precise, tunable and scalable nanomanufacturing of both rigid and flexible COVID sensor substrates, important for future implementation, not just on chip-based biosensors but also wearables,” said senior author David Gracias.

The platform goes beyond the current coronavirus pandemic, according to Barman. “We can use this for broad testing against different viruses, for instance, to differentiate between SARS-CoV-2 and H1N1, and even variants. This is a major issue that can’t be readily addressed by current rapid tests.”

The team continues to develop and test the technology and is pursuing a patent and potential license and commercialization opportunities.

A Rapid Graphene Sensor Platform for the Detection of Viruses in a Pinprick

Scientists at Swansea University, Biovici Ltd and the National Physical Laboratory have developed a method to detect viruses in very small volumes.

The work, published in Advanced NanoBiomed Research ("A Rapid Graphene Sensor Platform for the Detection of Viral Proteins in Low Volume Samples"), follows a successful Innovate UK project developing graphene for use in biosensors – devices that can detect tiny levels of disease markers.

For many parts of the world that do not have access to high-tech labs found in hospitals, detecting viruses such as hepatitis C (HCV) – could save millions of preventable deaths worldwide. In addition, biosensors such as this could be used at the point-of-care – opening effective healthcare in difficult-to-reach settings.

What makes the detection of viruses in such small volumes possible is the use of a material called graphene. Graphene is extremely thin - only one atom thick - making it very sensitive to anything that attaches to it. By carefully controlling its surface, scientists at Swansea University were able to make the surface of graphene sensitive to the HCV virus. These measurements were done with graphene specialists at the National Physical Laboratory.

In the future, it is hoped that multiple biosensors can be developed onto a single chip – this could be used to detect different types of dangerous viruses or disease markers from a single measurement.

Ffion Walters, Innovation Technologist at Swansea University’s Healthcare Technology Centre said: “Highly sensitive and simplistic sensors have never been more in demand with regards point-of-care applications. This collaborative project has allowed us to realise proof-of-concept real-time sensors for HCV, which could be especially beneficial in resource-limited settings or for difficult-to-reach populations.”

Professor Owen Guy, Head of Chemistry at Swansea University, said: “At Swansea University, we have now developed graphene-based biosensors for both Hepatitis B and C. This is a major step forward to a future single point of care test”

Dr Olga Kazakova, NPL Fellow Quantum Materials & Sensors added: “NPL was delighted to be part of this multidisciplinary team. Participation in this project allowed us to further develop our metrological validation facilities and apply them to the characterisation of graphene biosensors and aid in solving an important challenge in the health sector.”

Source: Swansea University

PRESS RELEASE: Cepheid Receives Emergency Use Authorization for Xpert® Xpress CoV-2 plus

Cepheid announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress CoV-2 plus, a rapid molecular diagnostic test for qualitative detection of the virus that causes COVID-19.

Viruses constantly change through mutation and these mutations can give rise to new variants with unique characteristics. Multiple variants of the virus that cause COVID-19 have been documented globally during the pandemic. Cepheid is proactively addressing this increasing genetic diversity by enhancing gene coverage. The new plus version of the test incorporates a 3rd conserved genetic target for SARS-CoV-2 detection to meet the challenge of future viral mutations and optimizes nucleocapsid gene probes to enable consistent virus detection.

Xpert Xpress CoV-2 plus joins Xpert® Xpress CoV-2/Flu/RSV plus and others in Cepheid's growing portfolio of PCRplus respiratory tests that deliver rapid, accurate, and actionable respiratory results. Xpert Xpress CoV-2/Flu/RSV plus continues to be the most appropriate product for when multiple viruses that cause influenza-like illnesses are circulating. Xpert Xpress CoV2 plus is authorized to be used on any individuals, including for screening those without symptoms or reasons to suspect COVID-19.(1)

Xpert Xpress CoV-2 plus is designed for use on any of Cepheid's over 40,000 GeneXpert® systems placed worldwide. The test can provide rapid on-demand detection of SARS-CoV-2 in as soon as 20 minutes for positive results.(2)  

"From the beginning of the pandemic, we have been keenly focused on staying ahead of SARS-CoV-2 genetic drift and have designed our tests in anticipation of current and potential future variants." said David Persing, M.D., Ph.D., EVP, and Chief Scientific Officer. "The high sensitivity of this test is now especially important for recently announced Test-to-Treat initiatives, for which early detection is important for achieving the best clinical outcomes of antiviral therapies."

Xpert Xpress CoV-2 plus is expected to begin shipping to US customers in May.

1.  PPA and NPA for asymptomatic specimens were calculated using anterior nasal swab specimens.

2.  With early assay termination for positives only; reporting of negatives in approximately 30 minutes.

Tuesday, April 19, 2022

FREDsense, Ginkgo Bioworks Partner to Make Water Quality Biosensors

FREDsense Technologies Corp, a water quality platform company, and Ginkgo Bioworks, a synthetic cellular biology company, today announced a partnership to build biosensors for water quality monitoring and detection.

Through this partnership, Ginkgo seeks to build four distinct microbial strain biosensors, compatible with FREDsense's field-ready hardware for remote water quality monitoring applications.

Water quality has become a growing environmental and public health concern, increasing the demand for scalable monitoring and testing systems. With conventional water quality tests, transporting samples to labs for chemical analysis can lead to lengthy delays in reporting. Some companies, like FREDsense, work to offer portable solutions that allow for rapid feedback without the need for external lab equipment.

"Water is our most critical resource, and we now have the technology to detect in real-time many of the threats or contaminants that can impact the water that our environments and communities depend on," says David Lloyd, CEO of FREDsense. "Through this partnership with Ginkgo, we aim to introduce rapid, simple, and accurate testing to deliver water quality monitoring systems to those that most need it. We believe that synthetic biology is the key to solving some of the biggest challenges facing the water industry globally and are very excited to partner with Ginkgo on this vision."

The biosensors in development by Ginkgo aim to enable real-time field detection of harmful molecules, and may be used to generate solutions for groundwater and industrial water management systems.

"Partnering with FREDsense is an exciting opportunity to apply Ginkgo's strain development capabilities to powerful biosensor technology for an important application," said Jason Kelly, CEO of Ginkgo Bioworks. "Protecting our water sources is a mission critical initiative: life on this planet as we know it depends on it. We're eager to work toward enhancing the capabilities of FREDsense's platform to monitor for harmful contaminants in water."

Johns Hopkins Scientists Develop New Sensor for Rapid COVID-19 Testing

A new sensor developed by researchers at Hopkins can detect communicable diseases like COVID-19, H1N1 and the Zika virus in saliva more accurately than traditional rapid tests at about the same speed.

The sensor relies on a combination of surface-enhanced Raman spectroscopy (SERS), machine learning, and large-area nanoimprint lithography. Researchers believe the technology could potentially boost public health safety measures in crowded locations. 

The project began about two years ago, near the start of the COVID-19 pandemic. The researchers started with detecting SARS-CoV-2 as their primary goal, but their work eventually expanded to include other infectious diseases like Zika, H1N1 and the Marburg virus. The results were published earlier this spring in Nano Letters.

Ishan Barman is an associate professor of mechanical engineering with joint appointments in the Sidney Kimmel Comprehensive Cancer Center and the Russell H. Morgan Department of Radiology and Radiological Science. Barman is one of the senior authors of the paper and the principal investigator of the lab that created the sensor.

He discussed the project’s beginnings in an interview with The News-Letter.

“When the first wave [of COVID-19] hit, it was explosive enough; it was a problem of large enough significance that even if it hadn’t continued for as long as it has, it would still have been a problem worth solving,” he said. “At the end of the day, a crucial step in controlling outbreaks is the timely and accurate calculation of emerging viruses.”

Debadrita Paria is a postdoctoral fellow in the Barman Lab. In an email to The News-Letter, Paria noted that the process of making the sensor was complicated by pandemic restrictions.

“It required rigorous planning and execution. We used to have several Zoom meetings where several ideas would come up and then we would go to the lab and try to implement those and see what worked. Since we were working in shifts, we had to do the experiments in a limited timeframe,” Paria wrote.

While PCR and rapid antigen tests are currently used for SARS-CoV-2 detection, researchers have pointed out their limitations. PCR tests require intense sample processing, including the use of fluorescent markers, to detect if COVID-19 RNA is present in a sample. Rapid antigen tests lack accuracy and have been hard to find because of high demand. Another challenge, according to the paper published in Nano Letters, is storing and transporting samples to be processed. 

Barman described how the sensor aims to counter those drawbacks. 

“We were always thinking that we need better sensing technology that combines the salient features of what we know: RT-PCR, which has incredible sensitivity and specificity, with the convenience and speed of the rapid antigen test,” he said.

The new sensor relies on a saliva sample instead of a more invasive nasal swab. Additionally, its accuracy for detecting COVID-19 is around 92%, which is comparable to PCR, the current gold standard. Finally, the sensor can work quickly, giving a positive or negative test result in about 12 minutes, according to Barman. The lab plans to continue working on reducing that time. 

Additionally, the sensor has built-in flexibility for SARS-CoV-2 mutations, meaning it will still be able to identify new variants. The team’s next goals are to work on identifying and differentiating these variants and to test real patient samples with the sensor to gauge how well it operates.

There are three components to how the sensor works: nanoimprint lithography, SERS and machine learning. The nanoimprint lithography provides a flexible surface for the saliva sample, using a field enhancing metal insulator antenna array to amplify the signal for the spectroscopy. 

SERS reads the sample relying on inelastic scattering of light to characterize how unique molecules vibrate. If COVID-19 or another infectious disease is present in the sample, there will be characteristic vibration patterns on the spectroscopy readout. 

The sensor then utilizes machine learning to determine if new samples are positive or negative based on what previous positive spectroscopy readouts looked like. According to the paper, using machine learning allows greater sensitivity and specificity to help overcome the noise from other unwanted biological specimens in the saliva sample. 

According to Barman, it can be placed on doorknobs, masks and other locations to help facilitate on-site rapid testing because of the flexibility of the surface used for the sample. He noted that the portable device to be used in those instances is about two shoeboxes tall. 

Barman highlighted that the new viral sensor has potential to be used as mass-testing technology not only for COVID-19 but also for other pathogens such as influenza, Zika virus and the Marburg virus. 

“We wanted to create a tool that would be better at managing outbreaks in the future. Thinking beyond the pandemic was always an objective,” he said.

Source: The Johns Hopkins News-Letter

Saturday, March 05, 2022

Purdue Receives Grant for Pursuit of African Swine Fever Rapid Test

African swine fever, a highly contagious swine disease, is in the Dominican Republic. The disease does not infect people, but it can wipe out pork production in a region. Quick identification and containment are key to stopping its spread, and a team of Purdue University researchers are developing a rapid, pen-side test for the disease.

The National Animal Health Laboratory Network and the National Animal Disease Preparedness and Response Program has provided $1 million to Mohit Verma, assistant professor of agricultural and biological engineering at Purdue, for the project.

“A rapid test that can be done in the field is needed for surveillance and diagnosis of African swine fever,” he said. “When it hit China a few years ago, it wiped out 50% of the country’s pig population. It is a devastating disease, and hours, even minutes, matter in containing it.”

The research funding was included in the U.S. Farm Bill to build up the nation’s ability to quickly detect and respond to high-consequence diseases.

“This was the first time to my knowledge that a joint operation between these two organizations was included in the farm bill,” Verma said. “It shows how seriously the U.S. is taking the risk from African swine fever.”

Verma is collaborating with Purdue scientists Darryl Ragland, associate professor of veterinary medicine, and Jonathan Alex Pasternak, an assistant professor of animal sciences, to create a portable paper-strip test for the disease. The project follows in the footsteps of Verma’s success developing similar tests for COVID-19 and Bovine Respiratory Disease.

“We’re working on a test that will detect the virus within 30 minutes and indicate results through an easy-to-see color change on a paper strip,” Verma said. “The ease of use, test timing and size are similar to those of an at-home pregnancy test or COVID-19 test.”

A saliva or blood sample will be used for the test. Within a cartridge, the sample is mixed with primers and reagents developed by the team and gently heated. The included paper strip then changes colors if African swine fever DNA is present, he said.

“We want the test to be easy for farmers and veterinarians, and for the pigs,” Verma said. “Our hope is to create something affordable and accessible that could be broadly used in the U.S. and throughout the world.”

The technology tests for DNA from the virus and uses a method of nucleic acid amplification called loop-mediated isothermal amplification, or LAMP. When the viral DNA is present, LAMP amplifies it. As the level of nucleic acid increases, it changes the pH of the assay, which triggers the color change on the paper strip.

The advantage of LAMP over other methods is that it does not require extraction and processing of the samples, which can be lengthy and expensive, Verma said

Saturday, January 29, 2022

Massachusetts Institute Of Technology: SMART Researchers Develop Method For Early Detection Of Bacterial Infection In Crops

Researchers from the Disruptive and Sustainable Technologies for Agricultural Precision (DiSTAP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, and their local collaborators from Temasek Life Sciences Laboratory (TLL), have developed a rapid Raman spectroscopy-based method for detecting and quantifying early bacterial infection in crops. The Raman spectral biomarkers and diagnostic algorithm enable the noninvasive and early diagnosis of bacterial infections in crop plants, which can be critical for the progress of plant disease management and agricultural productivity.

Due to the increasing demand for global food supply and security, there is a growing need to improve agricultural production systems and increase crop productivity. Globally, bacterial pathogen infection in crop plants is one of the major contributors to agricultural yield losses. Climate change also adds to the problem by accelerating the spread of plant diseases. Hence, developing methods for rapid and early detection of pathogen-infected crops is important to improve plant disease management and reduce crop loss.

The breakthrough by SMART and TLL researchers offers a faster and more accurate method to detect bacterial infection in crop plants at an earlier stage, as compared to existing techniques. The new results appear in a paper titled “Rapid detection and quantification of plant innate immunity response using Raman spectroscopy” published in the journal Frontiers in Plant Science.

“The early detection of pathogen-infected crop plants is a significant step to improve plant disease management,” says Chua Nam Hai, DiSTAP co-lead principal investigator, professor, TLL deputy chair, and co-corresponding author. “It will allow the fast and selective removal of pathogen load and curb the further spread of disease to other neighboring crops.”

Traditionally, plant disease diagnosis involves a simple visual inspection of plants for disease symptoms and severity. “Visual inspection methods are often ineffective, as disease symptoms usually manifest only at relatively later stages of infection, when the pathogen load is already high and reparative measures are limited. Hence, new methods are required for rapid and early detection of bacterial infection. The idea would be akin to having medical tests to identify human diseases at an early stage, instead of waiting for visual symptoms to show, so that early intervention or treatment can be applied,” says MIT Professor Rajeev Ram, who is a DiSTAP principal investigator and co-corresponding author on the paper.

While existing techniques, such as current molecular detection methods, can detect bacterial infection in plants, they are often limited in their use. Molecular detection methods largely depend on the availability of pathogen-specific gene sequences or antibodies to identify bacterial infection in crops; the implementation is also time-consuming and nonadaptable for on-site field application due to the high cost and bulky equipment required, making it impractical for use in agricultural farms.

“At DiSTAP, we have developed a quantitative Raman spectroscopy-based algorithm that can help farmers to identify bacterial infection rapidly. The developed diagnostic algorithm makes use of Raman spectral biomarkers and can be easily implemented in cloud-based computing and prediction platforms. It is more effective than existing techniques as it enables accurate identification and early detection of bacterial infection, both of which are crucial to saving crop plants that would otherwise be destroyed,” explains Gajendra Pratap Singh, scientific director and principal investigator at DiSTAP and co-lead author.

A portable Raman system can be used on farms and provides farmers with an accurate and simple yes-or-no response when used to test for the presence of bacterial infections in crops. The development of this rapid and noninvasive method could improve plant disease management and have a transformative impact on agricultural farms by efficiently reducing agricultural yield loss and increasing productivity.

“Using the diagnostic algorithm method, we experimented on several edible plants such as choy sum,” says DiSTAP and TLL principal investigator and co-corresponding author Rajani Sarojam. “The results showed that the Raman spectroscopy-based method can swiftly detect and quantify innate immunity response in plants infected with bacterial pathogens. We believe that this technology will be beneficial for agricultural farms to increase their productivity by reducing their yield loss due to plant diseases.”

The researchers are currently working on the development of high-throughput, custom-made portable or hand-held Raman spectrometers that will allow Raman spectral analysis to be quickly and easily performed on field-grown crops.

SMART and TLL developed and discovered the diagnostic algorithm and Raman spectral biomarkers. TLL also confirmed and validated the detection method through mutant plants. The research is carried out by SMART and supported by the National Research Foundation of Singapore under its Campus for Research Excellence And Technological Enterprise (CREATE) program.

SMART was established by MIT and the NRF in 2007. The first entity in CREATE developed by NRF, SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Center and five IRGs: Antimicrobial Resistance, Critical Analytics for Manufacturing Personalized-Medicine, DiSTAP, Future Urban Mobility, and Low Energy Electronic Systems. SMART research is funded by the NRF under the CREATE program.

Led by Professor Michael Strano of MIT and Professor Chua Nam Hai of Temasek Lifesciences Laboratory, the DiSTAP program addresses deep problems in food production in Singapore and the world by developing a suite of impactful and novel analytical, genetic, and biomaterial technologies. The goal is to fundamentally change how plant biosynthetic pathways are discovered, monitored, engineered, and ultimately translated to meet the global demand for food and nutrients. Scientists from MIT, TTL, Nanyang Technological University, and National University of Singapore are collaboratively developing new tools for the continuous measurement of important plant metabolites and hormones for novel discovery, deeper understanding and control of plant biosynthetic pathways in ways not yet possible, especially in the context of green leafy vegetables; leveraging these new techniques to engineer plants with highly desirable properties for global food security, including high-yield density production, and drought and pathogen resistance; and applying these technologies to improve urban farming.

Rapid Lyme Disease Tests Could Soon Be Heading to A Doctor’s Office Near You

A faster test for Lyme disease with results in as little as an hour could be available in doctor’s offices in the near future thanks to the efforts of two UCF researchers.

Mollie Jewett, associate professor and head of the Immunity and Pathogenesis Division at the College of Medicine and Brian Kim an assistant professor in the College of Engineering and Computer Science, will split a $325,000 grant over two years from the Global Lyme Alliance to create a rapid test that can detect the disease weeks earlier than current tests allow. The new test would eliminate the need to visit diagnostic labs and wait for the results.

Lyme disease is carried by deer ticks and infects people when they are bitten by ticks carrying the bacteria borrelia burgdorferi.  Deer ticks are especially common in the northeastern United States and people are exposed to the ticks usually during outdoor activities. Warming temperatures have helped tick populations explode and infiltrate more areas of the country increasing the chance of getting the disease.

The Centers for Disease Control and Prevention estimate that 476,000 people are infected with Lyme disease every year.

Early symptoms of Lyme disease are fever, headache, fatigue and the possibility of a telltale bullseye rash at the site of the bite. If left untreated, the infection can spread to the joints, heart, and nervous system and cause debilitating long-term conditions.

“Testing is a real obstacle for patients, the longer the patient goes without treatment the higher the potential for significant persistent symptoms,” says Jewett.  “Lyme disease antibodies takes up to 14 days to become detectable. By directly detecting the bacteria that causes Lyme disease, the test will fill the current blind spot in the time from infection to diagnosis.”

When the infection is caught early and treated with antibiotics in the preliminary stages, patients can recover quickly without long-term effects. Patients who are treated in later stages of the disease tend to respond well to antibiotics, however, some continue to suffer from ongoing symptoms, termed Post-treatment Lyme disease Syndrome.

Jewett is creating a molecular test that can not only test for antibodies in the blood specific for the infection, but also directly detect the bacteria that causes Lyme disease. The hand-held diagnostic device which the researchers call the Lyme iDS, combines Jewett’s molecular test with Kim’s detection device.

“The science and technology behind the device can be applied to many diseases using biological fluids such as blood in the case of Lyme disease,” says Kim who has successfully applied his testing device for detecting HIV, Zika virus, tuberculosis and COVID-19. His goals are to make testing easier, faster and cheaper by building a device with less expensive components that performs as well as current more expensive and bulky instruments.

Griffith Parks, the College of Medicine’s associate dean of Research and director of the Burnett School of Biomedical Sciences, praised the collaborative research project.

“This is prime example of how two outstanding researchers can partner to address an important biomedical problem from new complementary points of view,” says Parks.

“We are excited to have faculty from the College of Medicine working closely with the strong faculty in the College of Engineering and Computer Science.”

Source: UCF News